Unmask the genetic backbone of ibrutinib-relapsed chronic lymphocytic leukemia progression and Richter transformation

Wei-Ge Wang^{1

2}, Xiao-Yan Zhou^{1

2}, Xiao-Qiu Li^{1

2}

Affiliations

¹ Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
² Department of Oncology, Fudan University Shanghai Medical School, Shanghai 200032, China.

Editorial

Wei-Ge Wang et al. Ann Transl Med. 2018 Jun.

. 2018 Jun;6(11):234.

doi: 10.21037/atm.2018.05.34.

Wei-Ge Wang^{1

2}, Xiao-Yan Zhou^{1

2}, Xiao-Qiu Li^{1

2}

¹ Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
² Department of Oncology, Fudan University Shanghai Medical School, Shanghai 200032, China.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL.
Kadri S, Lee J, Fitzpatrick C, Galanina N, Sukhanova M, Venkataraman G, Sharma S, Long B, Petras K, Theissen M, Ming M, Kobzev Y, Kang W, Guo A, Wang W, Niu N, Weiner H, Thirman M, Stock W, Smith SM, Nabhan C, Segal JP, Lu P, Wang YL. Kadri S, et al. Blood Adv. 2017 May 2;1(12):715-727. doi: 10.1182/bloodadvances.2016003632. eCollection 2017 May 9. Blood Adv. 2017. PMID: 29296715 Free PMC article.

1. Kadri S, Lee J, Fitzpatrick C, et al. Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL. Blood Adv 2017;1:715-27. 10.1182/bloodadvances.2016003632 - DOI - PMC - PubMed
1. Landau DA, Tausch E, Taylor-Weiner AN, et al. Mutations driving CLL and their evolution in progression and relapse. Nature 2015;526:525-30. 10.1038/nature15395 - DOI - PMC - PubMed
1. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369:32-42. 10.1056/NEJMoa1215637 - DOI - PMC - PubMed
1. Maddocks KJ, Ruppert AS, Lozanski G, et al. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. JAMA Oncol 2015;1:80-7. 10.1001/jamaoncol.2014.218 - DOI - PMC - PubMed
1. Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med 2014;370:2286-94. 10.1056/NEJMoa1400029 - DOI - PMC - PubMed